Related Experiment Videos
Advanced lymphosarcoma treated by total body irradiation
The British Journal of Cancer. Supplement
|March 1, 1975
Summary
Total body irradiation (TBI) is an effective treatment for advanced lymphosarcoma, showing high response and remission rates. This study highlights TBI as a viable systemic agent for managing advanced lymphosarcoma.
Area of Science:
- Oncology
- Radiation Oncology
- Hematology
Background:
- Lymphosarcoma is a significant hematologic malignancy.
- Advanced stages (III and IV) present treatment challenges.
- Systemic treatment options for lymphosarcoma are continually being evaluated.
Purpose of the Study:
- To evaluate the efficacy and toxicity of total body irradiation (TBI) as a primary treatment for advanced lymphosarcoma.
- To assess response rates, remission duration, and survival outcomes.
- To compare TBI outcomes with other treatment modalities.
Main Methods:
- Retrospective analysis of 25 patients with clinical Stage III/IV lymphosarcoma.
- Primary treatment with total body irradiation (TBI) at 150 rad (15 rad twice weekly).
- Histological classification based on Rappaport criteria (nodular vs. diffuse).
Main Results:
- 80% complete response and 20% partial response rates observed.
- 64% of patients achieved continuous, unmaintained remission up to 39 months.
- Actuarial survival was 87% at 2 years; toxicity primarily thrombocytopenia.
Conclusions:
- Total body irradiation (TBI) demonstrates significant efficacy as a systemic agent for advanced lymphosarcoma.
- TBI offers high response and durable remission rates with manageable toxicity.
- TBI should be considered in the management of advanced lymphosarcoma.